|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4,089 JPY | -0.02% |
|
+0.49% | +0.86% |
| Apr. 26 | EU Panel Backs Approval of Takeda’s Colorectal Cancer Drug | MT |
| Apr. 26 | Hutchmed notes CHMP's positive opinion for fruiquintinib approval | AN |
Feb 12 (Reuters) - Drugmaker Takeda said on Monday the U.S. Food and Drug Administration has approved its therapy for a type of allergic inflammation of the esophagus, making it the first oral treatment for the condition. (Reporting by Sriparna Roy in Bengaluru; Editing by Krishna Chandra Eluri)
Price
|
Change
|
5d. change
|
Capi.
| ||
|---|---|---|---|---|---|
| 4,089 JPY | -0.02% | +0.49% | 40.76B | ||
| 2,686 PTS | +0.86% | +0.34% | - | ||
| 1st Jan change | Capi. | |
|---|---|---|
| +0.86% | 40.76B | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
TAKEDA PHARMACEUTICAL COMPANY LIMITED 
